- Home
- NXGL vs BIVI Comparison
NXGL vs BIVI Comparison
Compare NXGL & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- BIVI
- Stock Information
- Founded
- NXGL 1997
- BIVI 2013
- Country
- NXGL United States
- BIVI United States
- Employees
- NXGL N/A
- BIVI N/A
- Industry
- NXGL Medical/Dental Instruments
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- BIVI Health Care
- Exchange
- NXGL Nasdaq
- BIVI Nasdaq
- Market Cap
- NXGL 18.9M
- BIVI 18.8M
- IPO Year
- NXGL 2021
- BIVI N/A
- Fundamental
- Price
- NXGL $2.85
- BIVI $0.95
- Analyst Decision
- NXGL
- BIVI Strong Buy
- Analyst Count
- NXGL 0
- BIVI 1
- Target Price
- NXGL N/A
- BIVI $30.00
- AVG Volume (30 Days)
- NXGL 48.6K
- BIVI 230.4K
- Earning Date
- NXGL 03-24-2025
- BIVI 05-13-2025
- Dividend Yield
- NXGL N/A
- BIVI N/A
- EPS Growth
- NXGL N/A
- BIVI N/A
- EPS
- NXGL N/A
- BIVI N/A
- Revenue
- NXGL $8,688,000.00
- BIVI N/A
- Revenue This Year
- NXGL $51.39
- BIVI N/A
- Revenue Next Year
- NXGL $36.14
- BIVI N/A
- P/E Ratio
- NXGL N/A
- BIVI N/A
- Revenue Growth
- NXGL 112.47
- BIVI N/A
- 52 Week Low
- NXGL $1.84
- BIVI $0.80
- 52 Week High
- NXGL $5.10
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- NXGL 45.24
- BIVI 37.09
- Support Level
- NXGL $2.60
- BIVI $0.99
- Resistance Level
- NXGL $3.25
- BIVI $1.10
- Average True Range (ATR)
- NXGL 0.23
- BIVI 0.10
- MACD
- NXGL 0.03
- BIVI 0.01
- Stochastic Oscillator
- NXGL 38.08
- BIVI 34.07
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.